Annexin A3 (ANXA3) is a calcium-binding protein that plays a role in membrane phospholipid metabolism and inflammation, and significant alterations have been shown in some psychotic disorders. Because its association with major depressive disorder (MDD) is unclear, we aimed to compare serum ANXA3 levels in patients with MDD and healthy controls and to investigate their relationship with depression severity. Serum ANXA3 concentrations in 90 patients diagnosed with MDD and 90 healthy controls were measured by ELISA. Depression severity was assessed using the Beck Depression Inventory (BDI). Serum ANXA3 levels were significantly lower in patients with MDD compared to controls (p < 0.001). ANXA3 showed negative correlations with neutrophil count, platelet count, neutrophil-to-lymphocyte ratio (NLR), glucose, creatinine, and ALT levels, and positive correlations with lymphocyte and red blood cell counts. We found that low ANXA3 levels, high NLR, and glucose dysregulation predicted greater depression severity. Using ROC analysis, we demonstrated that ANXA3 has high discriminatory power in distinguishing moderate to severe cases of MDD (AUC > 0.90). ANXA3 may serve as a biomarker of depression severity. Further studies are needed to clarify its clinical utility and confirm whether ANXA3 alterations represent state or trait markers of depression.

Background and Objectives: Klotho (KL) is a multifunctional protein involved in reproductive physiology; however, its precise role in ovarian reserve and in vitro fertilization (IVF) outcomes remains unclear. This study aimed to evaluate the relationship between follicular fluid KL levels, ovarian reserve markers, and key IVF success parameters. Materials and Methods: This prospective study included a total of 150 women undergoing IVF, of whom 82 had diminished ovarian reserve (DOR) and 68 had normal ovarian reserve (NOR). All participants underwent controlled ovarian stimulation using a standard antagonist protocol. During oocyte pick-up (OPU), the first aspirated follicular fluid sample was collected, processed, and analyzed for KL concentrations using a Human Klotho ELISA kit. Hormonal profiles, ovarian reserve markers, and IVF outcomes were compared between groups. Results: Follicular fluid KL levels were significantly lower in the DOR group compared with the NOR group (117.07 ± 28.88 pg/mL vs. 266.13 ± 58.29 pg/mL; p < 0.001). Anti-Müllerian hormone (AMH) levels were reduced, whereas follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) levels were significantly higher in the DOR group (all p < 0.001). Implantation and clinical pregnancy rates were also significantly lower in the DOR group compared with the NOR group (p < 0.001 and p = 0.003, respectively). KL levels showed a strong positive correlation with the number of fertilized oocytes in both groups (DOR: r = 0.690; NOR: r = 0.552). Each one-unit increase in KL was associated with a 3.7% increase in implantation probability and a 3.2% increase in clinical pregnancy probability in the DOR group, and with corresponding increases of 4.4% and 1.2% in the NOR group (all p < 0.05). Conclusions: This study demonstrates significant associations between follicular fluid KL levels and fertilization, implantation, and clinical pregnancy outcomes. These associations appear to be more pronounced than those observed with traditional ovarian reserve markers such as AMH and antral follicle count. Reduced KL levels are associated with fewer fertilized oocytes, whereas higher KL concentrations correspond to increased implantation and clinical pregnancy probabilities. Nevertheless, similar to other non-invasive biomarkers, current evidence is insufficient to support routine clinical use of KL. Large-scale, well-designed, multicenter studies are therefore required to validate its clinical relevance and to determine whether KL can serve as a reliable and practical predictor of IVF success.

Objective: This study aimed to evaluate the relationship between CD27, CD28, CD81, and CD117 antigens and clinical, biochemical, and cytogenetic parameters in patients with multiple myeloma (MM) and to evaluate their prognostic significance.Material and Methods: A retrospective analysis was performed on data from 100 multiple myeloma patients. The analysis included available flow cytometry data (CD27, CD28, CD81, and CD117) and bone marrow biopsy results. Demographic data, laboratory parameters, cytogenetic analyses, treatment responses, and mortality were recorded. Multivariate logistic regression analysis was performed for variables associated with the R-ISS stages.Results: The median age of the patients was 67 years, and 64% were men. The positivity rates for CD27, CD28, CD81, and CD117 were 45%, 53%, 61%, and 51%, respectively. As the R-ISS stage increased, CD27 negativity significantly increased (p=0.021), while CD117 positivity also increased (p=0.046). In the multivariate analysis, CD28 positivity emerged as an independent risk factor for a higher R-ISS stage (aOR=0.324 for CD28 negativity, p=0.015). CKS1B positivity (p=0.039) and a high bone marrow plasma cell ratio (p=0.004) were independently associated with advanced disease stages. As the R-ISS stage increased, ECOG performance scores worsened, and the number of lytic lesions and mortality rates significantly increased.Conclusion: In multiple myeloma, CD27 loss and CD117 positivity are associated with poor prognosis, whereas CD28 positivity is associated with more advanced disease stage. The addition of these immunophenotypic markers to the R-ISS classification may contribute to a more accurate assessment of biological risk and the development of personalized treatment plans.